FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
-
By
-
Kathryn Wighton
-
May 29, 2026
-
Clinical Scorecard: FDA Expands Guselkumab Label in PsA
At a Glance
| Category | Detail |
|---|
| Condition | Active Psoriatic Arthritis (PsA) |
| Key Mechanisms | Inhibition of structural joint damage progression |
| Target Population | Adults with active psoriatic arthritis at risk for joint damage |
| Care Setting | Outpatient care for biologic-naïve patients |
Key Highlights
- Guselkumab approved for inhibition of structural joint damage in PsA
- Supported by phase 3b APEX trial results
- 57% reduction in radiographic progression from weeks 24 to 48 for patients switching from placebo
- No new safety signals identified
- Only interleukin-23 inhibitor with structural inhibition in US prescribing information
Guideline-Based Recommendations
Diagnosis
- Diagnosis of PsA based on clinical criteria and imaging
Management
- Guselkumab as a treatment option for patients with inadequate response to standard therapies
Monitoring & Follow-up
- Monitor for joint symptoms and progression of structural damage
Risks
- Potential for irreversible joint damage if untreated
Patient & Prescribing Data
Biologic-naïve adults with active PsA
Guselkumab shows significant efficacy in reducing joint symptoms and structural damage
Clinical Best Practices
Related Resources & Content
